C-Peptide
For informational purposes only — not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen. Full disclaimer →
- C-peptide directly measures pancreatic insulin output without hepatic interference. The liver clears roughly half of insulin from portal blood before it reaches systemic circulation, making fasting insulin an indirect measure that varies with liver extraction efficiency. C-peptide bypasses this confound completely — it is not extracted by the liver, and its circulating level more accurately reflects the total volume of insulin being secreted by the pancreas.
- C-peptide distinguishes two very different metabolic states: insulin overproduction vs. beta cell exhaustion. High C-peptide with normal glucose indicates the pancreas is compensating for insulin resistance — still functional but working harder. Low C-peptide with elevated glucose indicates the pancreas is failing to produce enough insulin regardless of resistance level — beta cell burnout. These two states have different implications for disease trajectory, medication choices, and intervention urgency.
- C-peptide rises before fasting glucose and HbA1c in the progression toward type 2 diabetes. The metabolic compensation phase — elevated C-peptide with normal glucose — can last for years or decades before glucose markers shift. During this window, the condition is most reversible and most responsive to lifestyle intervention. C-peptide detects this earlier than conventional glucose tests.
- C-peptide is the only way to assess residual insulin production in someone using injected insulin. Exogenous insulin injections contain no C-peptide. In a person with type 1 or late-stage type 2 diabetes who uses insulin, C-peptide is the only test that can distinguish whether they still have any beta cell function remaining — information that is clinically important for determining insulin requirements, hypoglycemia risk, and whether certain medications might still be effective.
- C-peptide tracks metabolic improvement more reliably than insulin. As insulin resistance improves with diet, exercise, and weight loss, the pancreas reduces compensatory insulin output. Falling C-peptide toward the lower half of the normal range is objective evidence that metabolic health is improving — the pancreas is doing less work because less compensation is needed.
The Problem with Fasting Insulin Alone
Fasting insulin has become a standard marker in longevity medicine, and for good reason. Chronically elevated fasting insulin predicts type 2 diabetes, cardiovascular disease, and all-cause mortality years before fasting glucose shifts. It captures insulin resistance at a stage when the condition is still reversible.
But fasting insulin has a structural limitation that most longevity practitioners don't discuss: the liver.
Insulin produced by the pancreas enters the portal circulation and travels directly to the liver, where approximately 50% is extracted and metabolized before reaching systemic blood. This hepatic first-pass extraction means that the fasting insulin level measured in a peripheral blood draw reflects both pancreatic secretion and the liver's extraction efficiency — two different variables bundled into one number. Two people can have identical pancreatic insulin output and meaningfully different fasting insulin levels based on differences in their hepatic insulin extraction.
C-peptide is produced in equal amounts to insulin but is not extracted by the liver. It travels from the pancreas to systemic circulation in nearly its full concentration, providing a cleaner measure of actual pancreatic secretion. This is why C-peptide was historically considered the gold standard for insulin secretion measurement in research settings — and why it adds genuine information beyond fasting insulin in clinical longevity assessment.
The Metabolic Timeline: What C-Peptide Reveals at Each Stage
Understanding where a person is on the metabolic health spectrum requires knowing both what the pancreas is producing and how effectively that insulin is being used. C-peptide maps the pancreatic side of this equation.
Stage 1 — Optimal metabolic health: Fasting C-peptide in the lower half of the normal range (0.8–1.5 ng/mL). The pancreas produces a modest, appropriate amount of insulin and tissues respond efficiently. Fasting glucose, fasting insulin, and HbA1c are all optimal.
Stage 2 — Compensated insulin resistance: C-peptide elevated above 2.0–2.5 ng/mL with normal or mildly elevated fasting insulin, but still-normal fasting glucose and HbA1c. The pancreas is working overtime to maintain glucose homeostasis in the face of growing insulin resistance. This is the most critical window for intervention — beta cell function is intact, the condition is fully reversible, and glucose tests look deceptively normal.
Stage 3 — Progressive decompensation: C-peptide may begin to plateau or fall as years of compensatory hypersecretion begin to exhaust beta cell capacity. Fasting glucose rises into the pre-diabetic range. HbA1c climbs above 5.7%. The trajectory toward type 2 diabetes is established.
Stage 4 — Beta cell exhaustion: C-peptide low or declining despite elevated glucose. The pancreas can no longer compensate. Type 2 diabetes declared. Treatment decisions now depend partly on C-peptide level — is there still residual beta cell function to preserve, or has the secretory capacity been largely lost?
| C-Peptide Level (Fasting) | Interpretation | Action |
|---|---|---|
| 0.8–2.0 ng/mL | Longevity optimal range | Maintain metabolic health practices |
| 2.0–3.1 ng/mL | Compensatory hyperinsulinemia | Dietary and lifestyle intervention; track trend |
| > 3.1 ng/mL | Significant insulin resistance / pancreatic stress | Clinical evaluation; prioritize metabolic intervention |
| < 0.8 ng/mL | Low pancreatic output | Evaluate for type 1 diabetes, late T2D, or other cause |
| Range Type | Value (ng/mL) | Notes |
|---|---|---|
| Standard Clinical Range | Fasting: 0.8–3.1 ng/mL (1.1–4.4 nmol/L) | Designed to identify disease risk — not longevity optimisation. |
| Longevity-Optimal Target | Fasting: 0.8–2.0 ng/mL |
Associated with reduced all-cause mortality and extended healthspan.
While the standard range extends to 3.1 ng/mL, a fasting C-peptide above 2.0–2.5 ng/mL in a non-diabetic adult typically reflects compensatory hyperinsulinemia — the pancreas working overtime to overcome insulin resistance. This is clinically meaningful even when fasting glucose and HbA1c are still normal, representing the pre-diabetic phase where metabolic dysfunction is present but not yet captured by glucose markers. C-peptide should be interpreted alongside fasting insulin and HbA1c for complete metabolic picture. In people who have lost significant weight or improved insulin sensitivity through lifestyle intervention, falling C-peptide toward the lower half of the normal range is a positive sign of reduced pancreatic burden.
|
Already have your results? See what your C-Peptide and other markers reveal about your longevity in 60 seconds.
Analyze My Labs →Affiliate disclosure: we may earn a commission if you purchase through these links at no extra cost to you.
If I already test fasting insulin, do I need C-peptide?
They measure related but distinct things. Fasting insulin reflects the amount of insulin reaching peripheral blood — which depends not only on how much the pancreas secretes but on how much the liver extracts first. C-peptide reflects what the pancreas actually produced. For most people with normal liver function and no history of insulin use, fasting insulin and C-peptide will trend together and either alone provides useful information. C-peptide adds the most when you want to (1) distinguish the insulin-resistant-but-compensating state from early beta cell decline, (2) track recovery of insulin sensitivity over time with objective proof that the pancreas is producing less, or (3) assess residual pancreatic function in someone who uses injected insulin. For a general metabolic assessment, fasting insulin is the more established marker. For deeper metabolic characterization — particularly in someone with pre-diabetes, family history of type 2 diabetes, or a history of significant weight gain — C-peptide alongside fasting insulin provides more complete information.
What does a high fasting C-peptide with normal blood sugar mean?
A fasting C-peptide consistently above 2.5 ng/mL in a person with normal fasting glucose and normal HbA1c is a meaningful early warning. It means the pancreas is producing substantially more insulin than a metabolically healthy person would need to maintain normal glucose — a state called compensatory hyperinsulinemia. The blood sugar looks normal on conventional tests precisely because the pancreas is working overtime to keep it there. This compensation can last years to decades, during which time insulin resistance is progressive and metabolic damage is accumulating — to the cardiovascular system, to adipose tissue, and to the beta cells themselves, which eventually become exhausted from chronic overwork. This window — elevated C-peptide with normal glucose — is the optimal time for intervention, because beta cell function is still intact and the condition is most reversible. Diet quality, caloric balance, and exercise load are the primary levers at this stage.
How should I prepare for a C-peptide test?
C-peptide should be drawn in a fasting state — typically after 8–12 hours without food or caloric beverages. This is the same preparation as fasting insulin and fasting glucose. Post-meal C-peptide is used in specific clinical contexts (stimulated C-peptide testing to assess maximum beta cell output), but for longevity monitoring, fasting C-peptide is the standard measure. Some medications can affect C-peptide levels: sulfonylureas (a class of diabetes medications including glipizide and glibenclamide) directly stimulate insulin secretion and will elevate C-peptide artificially. GLP-1 agonists (semaglutide, liraglutide) stimulate glucose-dependent insulin secretion. If you are on either of these medications, note this when interpreting results. Exogenous insulin itself does not affect C-peptide levels (which is why C-peptide is so useful in insulin-treated patients).
What is the HOMA-β calculation and how does C-peptide factor in?
HOMA-β (Homeostatic Model Assessment of beta cell function) is a mathematical formula that estimates beta cell function from fasting glucose and fasting insulin. It provides a composite index rather than a direct measurement. C-peptide can be substituted for insulin in modified versions of this calculation, and some researchers argue C-peptide provides more accurate beta cell function estimates because it avoids the hepatic extraction confound of insulin. In clinical longevity practice, most practitioners look at C-peptide, fasting insulin, and glucose trends together rather than relying on any single composite score. A trajectory that shows falling C-peptide with rising fasting glucose over consecutive years is a clear signal of progressing beta cell dysfunction — no formula required to see the pattern.